Cosette loses appeal over failed $672M Mayne merger
An appeals court has found US drug maker Cosette could not rely on sales performance figures to justify its termination of a $672 million merger agreement with Mayne Pharma Group.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
